Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer

MLA

Elaine W. Kay, et al. “Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer.” Clinical Cancer Research, vol. 16, June 2010, pp. 3442–51. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....39220bb9a2af974761c52b8ffd4e9ef7&authtype=sso&custid=ns315887.

APA

Elaine W. Kay, Ultan McDermott, Victoria Coyle, Sandra Van Schaeybroeck, Cliona McDowell, Patrick G. Johnston, S. Conlon, Helen L. Barrett, Richard H. Wilson, Daniel B. Longley, Robert Cummins, & Donal P. McLornan. (2010). Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer. Clinical Cancer Research, 16, 3442–3451.

Chicago

Elaine W. Kay, Ultan McDermott, Victoria Coyle, Sandra Van Schaeybroeck, Cliona McDowell, Patrick G. Johnston, S. Conlon, et al. 2010. “Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer.” Clinical Cancer Research 16 (June): 3442–51. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....39220bb9a2af974761c52b8ffd4e9ef7&authtype=sso&custid=ns315887.